Black Diamond Therapeutics, Inc.BDTX
What Black Diamond Therapeutics, Inc. does.
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways. Our lead clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). We plan to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR altered glioblastoma (GBM) in the second quarter of 2026.
Our goal is to bring targeted oncology medicine to patients with genetically defined cancers who have limited treatment options. Our drug development efforts leverage our novel findings that:
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | $0 | $70.0M |
| Net income | -$67.3M | -$125.6M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| Free cash flow | -$52.3M | -$102.9M | -$85.3M | -$66.8M | -$62.3M | — |
More on BDTX.
- Black Diamond Therapeutics, Inc. summary
- Black Diamond Therapeutics, Inc. financial statements
- Black Diamond Therapeutics, Inc. key metrics
- Black Diamond Therapeutics, Inc. health scores and style box
- Black Diamond Therapeutics, Inc. earnings
- Black Diamond Therapeutics, Inc. dividends
- Black Diamond Therapeutics, Inc. valuation
- Black Diamond Therapeutics, Inc. ownership and insiders
- Black Diamond Therapeutics, Inc. peers
Figures from Black Diamond Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.